I'm LongbridgeAI, I can summarize articles.Merck fell 3.01% this week to close at $144.3, underperforming the S&P 500 by roughly 2.74 percentage points. The week traced a rise-and-fade pattern: it climbed above $149 early in the week before breaking below the prior close on Wednesday, sliding further on Thursday, and steadying on Friday after an intraday low of $142.73. Weekly amplitude was 5.17%, with volume only about 2.26% above its own median, so no unusual turnover stood out. The 60-day range high sits at $156.
The Week
Merck fell 3.01% this week to close at $144.3, underperforming the S&P 500 by roughly 2.74 percentage points. The week traced a rise-and-fade pattern: it climbed above $149 early in the week before breaking below the prior close on Wednesday, sliding further on Thursday, and steadying on Friday after an intraday low of $142.73. Weekly amplitude was 5.17%, with volume only about 2.26% above its own median, so no unusual turnover stood out. The 60-day range high sits at $156.92, leaving the current price some distance from that level.
Key Events
Merck’s story this week centred on oncology pipeline moves and collaborations. On Monday, the company entered into an exclusive global licence agreement with SciBrunch Therapeutics for SPR2015, an oral KRAS G12D (ON) inhibitor; follow-up coverage put the upfront payment at $400 million and the total deal value around $2.13 billion. The same week, Merck and Daiichi Sankyo withdrew an FDA application for a lung cancer drug. On Wednesday, Merck said tulisokibart met the primary and key secondary endpoints in a Phase 2b trial for moderate-to-severe hidradenitis suppurativa, and later scheduled its third-quarter sales and earnings call. On the industry side, the trend of major drugmakers turning to China for licensing deals recurred through the week.
Analyst Ratings
Among 27 institutions covering Merck, 14 rate it buy, 5 overweight and 8 hold; none rate it underweight or sell. The consensus rating is buy, with a consensus target of $155.76, about 7.94% above spot. Targets span a wide range from $105 to $186, pointing to clear disagreement about the valuation outlook. Merck ranks fourth within its pharma industry coverage, toward the top of the peer group.
The Week Ahead
The coming week’s key macro prints include final S&P Global services PMI and ISM non-manufacturing PMI on Monday, followed by international trade data on Tuesday, all of which could shape risk appetite. On the company side, Merck has scheduled its third-quarter sales and earnings call, but the formal results release is set for October 29 pre-market, so next week is not yet an earnings checkpoint. Follow-through on the withdrawn FDA application and the KRAS deal also bears watching.
In Short
Merck’s share price softened this week and lagged the broader market, yet the institutional picture remains constructive: consensus rating is buy and the consensus target sits 7.94% above spot. At the same time, valuation pressure is clear, with PE around 112x and PB around 8.49x, while the latest day’s fund flow shows large-lot net selling against small-lot net buying. New R&D deals and pipeline data offer upside room, but the withdrawn filing and rich valuation need further signals to resolve the tension. The immediate question is whether macro data can steady market sentiment and whether the third-quarter update can anchor the current price.
This article is generated by LongbridgeAI from market data, for information only and not investment advice.